Table 2.
Characteristics of studies showing mode of diagnosis and prevalence of methane positive SIBO in IBS patients
| No | Author | Study Year | Country | IBS, n |
IBS Subtype IBS-D IBS-C IBS-M |
Criteria for IBS diagnosis | Controls n | Type of control | Mode of diagnosis | Methane Positive SIBO in IBS, n (%) |
Methane positive SIBO in IBS subtypes, n (%) IBS-D IBS-C IBS-M |
Methane positive SIBO in controls, n (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shah A et al46 | 2020 | Australia | 62 | 18 | 8 | 38 | Rome IV | 63 | Healthy controls | GBT | 4 (25) | 1 (6.3) | 1 (6.3) | 2 (12.5) | 5 (31.3) |
| 2 | Ghoshal U et al12 | 2018 | India | 23 | NA | 23 | - | Rome III | 68 | Non-constipating IBS | LBT | 13 (56.5) | NA | 13 (56.5) | - | 25 (36.8) |
| 3 | Ghoshal U et al29 | 2016 | India | 25 | 13 | 12 | NA | Rome III | NA | NA | LBT | 8 (66.7) | 3 (23.1) | 8 (66.7) | NA | NA |
| 4 | Vega AB et al38 | 2015 | Spain | 48 | NA | 48 | NA | Rome III | 19 | Healthy controls | LBT | 29 (60.4) | NA | 29 (60.4) | NA | 10 (52.6) |
| 5 | Lee KN et al48 | 2013 | Korea | 68 | 35 | 23 | 10 | Rome III | 55 | Healthy controls | LBT | 10 (14.7) | 21 (60) | 14 (60.9) | 7 (70) | 5 (9.1) |
| 6 | Rana S et al36 | 2012 | India | 175 | 175 | NA | NA | Rome II | 150 | Healthy controls | GBT | 0 | 0 | NA | NA | 0 |
| 7 | Park JS et al31 | 2010 | Korea | 76 | 45 | 12 | 19 | NA | 40 | Healthy controls | LBT | 25 (32.9) | 14 (31.1) | 4 (33.3) | 7 (36.8) | 13 (32.5) |
| 8 | Hwang L et al39 | 2010 | USA | 56 | 23 | 24 | 9 | Rome I | NA | NA | LBT | 28 (50) | 6 (26.1) | 22 (91.7) | - | NA |
| 9 | Parodi A et al32 | 2009 | Italy | 130 | 51 | 31 | 48 | Rome III | 70 | Healthy controls | GBT | 35 (26.9) | 11 (21.6) | 10 (32.3) | 14 (29.2) | 17 (24.3) |
| 10 | Scarpellini E et al37^ | 2009 | Italy | 43 | 15 | 12 | 16 | Rome II | 56 | Healthy controls | LBT | 4 (9.3) | - | - | - | 0 |
| 11 | Bratten J et al27 | 2008 | USA | 224 | 114 | 92 | - | Rome II | 40 | Healthy controls | LBT | 44 (19.6) | 13 (11.4) | 25 (27.2) | - | 6 (15) |
| 12 | Majewski M et al40 | 2007 | USA | 204 | 149 | 30 | 25 | Rome II | NA | NA | GBT | 32 (15.7) | 20 (13.4) | 7 (23.3) | 4 (16) | NA |
| 13 | Chatterjee S et al28 | 2007 | USA | 87 | NA | NA | NA | Rome I | NA | NA | LBT | 20 (23) | NA | NA | NA | NA |
| 14 | Pimentel M et al33 | 2006 | USA | 39 | NA | 39 | NA | Rome I | NA | NA | LBT | 12 (30.8) | NA | 12 (30.8) | NA | NA |
| 15 | Pimentel M et al34 | 2003 | USA | 65 | 34 | 31 | NA | Rome I | NA | NA | LBT | 12 (24.0) | 0 | 12 (38.7) | NA | NA |
| 16 | Pimentel M et al35 | 2003 | USA | 296 | 111 | 120 | 65 | Rome I | NA | NA | LBT | 50 (16.9) | 6 (5.4) | 30 (25) | NA | NA |
| 17 | Peled Y et al47 | 1987 | Israel | 32 | 6 | 16 | - | Breath methane | 152 | Healthy controls | NA | 11 (34.4) | 1 (16.7) | 5 (31.3) | - | 76 (50) |
IBS: Irritable bowel syndrome; SIBO: small intestinal bacterial overgrowth; LBT: lactulose breath test; GBT: glucose breath test; IBS-D: IBS-diarrhea; IBS-C: IBS-constipation; IBS-M: IBS-mixed; NA: not applicable, ^ Study included pediatric patients with a diagnosis of IBS, *Information not available.